Hyderabad-based Biological E. Limited (BE)’s COVID-19 vaccine Corbevax has been approved by the Drug Controller General of India (DCGI) as a heterologous COVID-19 booster dose to individuals aged 18 years and above after 6 months of administration of primary vaccination (two doses) of Covaxin or Covishield vaccines for restricted use in emergency situations.
In a release issued on Saturday, the company said that Corbevax is the first such vaccine in India to be approved as a heterologous COVID-19 booster. A heterologous booster is when the third dose is different from the earlier doses.
‘’Recently, BE furnished its clinical trials data to the DCGI, who after a detailed evaluation and deliberations with Subject Experts Committee, granted their approval for administering Corbevax vaccine as a heterologous booster dose to people who have already taken two doses of either Covishield or Covaxin,’’ said the release.
